Gain of function mutations in KRAS and
Introduction
KRAS signaling and was derived from interrogating gene expression in lung, breast, and colon cancer datasets. The transcriptional readout was suggested to be superior to KRAS status as a predictor of RAS-ERK pathway dependence and predictive of sensitivity to MEKi. The Dry et al 18-gene ("MEK signature") captured signaling exclusively from MEK and was able to stratify MEK pathway activation and/or MEKi sensitivity in lung, breast, colon, and melanoma cell lines and xenograft models. Dry et al also described a 13-gene ("CRes signature") linked to MEK-independent RAS signaling and resistance to MEKi. Both gene signatures were developed in silico from pan-cancer datasets generated from microarray measurements of frozen tumor samples or cell lines.
The application of microarrays for clinical investigation is compromised by cost, reproducibility, failure rate, and pre-analytical requirements for tumor tissue quantity and quality (10, 11) . Thus, there is a fundamental need to transfer gene signatures to a platform capable of robustly profiling small amounts of RNA extracted from formalin-fixed paraffin-embedded tissue (FFPET), the typical clinical sample type.
Furthermore, consistent scores on repeat testing is imperative across technical variables such as RNA input, reagent-batch, and selection of a representative area of tissue for testing.
In addition to a technically validated assay, a valid biomarker hypothesis is required.
To be a successful predictive biomarker, gene signature profiles should be consistent within a tumor sample such that multiple testing would elicit the same treatment decision for the patient. Finally, it is important to understand whether biomarker data from a diagnostic sample expression profile is clinically relevant following the genetic and phenotypic changes that can occur under the selective pressure of treatment.
Research.
on October 24, 2017. © 2016 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on October 12, 2016; DOI: 10.1158/1078-0432.CCR- [16] [17] [18] [19] [20] [21] We selected the NanoString nCounter™ expression system to study the MEK (plus associated CRes) (8) and RAS (9) gene signatures. This probe-based technology measures mRNA abundance in low amounts of total RNA without enzyme reactions and subsequent bias; has demonstrated greater sensitivity than microarrays (12) ; and has demonstrated superior results with archived FFPET specimens compared with RT-qPCR (13) . The degree of multiplexing offered by the technology is relevant to our gene signature size; additionally, it has demonstrated potential with gene signatures in several clinical studies (14) (15) (16) ).
Here we describe the steps taken to convert the published MEK and RAS signatures to a NanoString format consistent with the quantity and quality of tumor tissue specimens routinely available from patients with NSCLC. Furthermore, we systematically addressed technical parameters (e.g., reagent batch variability, limit of detection [LOD] , and quantification [LOQ] ) and biological variables (studying the association with activating KRAS mutations, spatiotemporal variation) necessary for clinical hypothesis testing. 
Materials and Methods

Refinement of the MEK signature
A sequential annotation and scoring approach assigned a tissue-specific weighting to each of the original 18 MEK signature genes. For each gene in each tumor tissue type, scores of 0 to 4 were assigned to the following features within NSCLC datasets (17) (18) (19) (20) : reproducibility of mRNA expression bimodality and intra-signature gene correlation across cell lines and patient samples; predictivity of selumetinib response in cell lines and in vivo xenograft models; consistent mRNA expression knockdown following MEK inhibition in cell lines and in vivo xenograft models; and predictivity of KRAS activation in patient samples. A final score (0 to 4) was assigned, based on rounded mean score for each feature, to select the most important genes in NSCLC.
Bimodality was considered positive if default thresholds were met in >1 dataset using the algorithm BiSep (21) (incorporating the Bimodality Index (22) ). Co-regulation was depending on whether data were from the Affymetrix array or RNAseq platform, respectively. Predictivity of drug response was considered positive for a gene if mean expression in sensitive cell lines (<1 µM GI50) was higher than resistant (>5 µM GI50), and all outlier low expressing samples were resistant. Predictivity of pathway activation was considered positive if, in >1 dataset, mean expression was higher in BRAF V600E or KRAS G12 mutant samples than wild-type, and all outlier low expressing samples were wild-type. Dynamic expression was considered 
Affymetrix data
NanoString cell line data were generated and compared with historical Affymetrix data using Pearson's correlation (23) . For each cell line, 4 μg of total RNA were isolated (RNeasy Mini Kit, QIAGEN, Hilden, Germany) and gene expression was measured using Affymetrix HG U133 Plus 2.0 GeneChip arrays following standard protocol (23, 24) . Affymetrix gene expression was quantified by robust multiarray analysis (25) , and data collapsed gene-centrically (EntrezID) following probe-set QC (23) . Data are available via the Gene Expression Omnibus (26), accession GSE57083.
NanoString nCounter codeset design
The codeset was designed by NanoString Inc (Seattle, WA) and comprised 18 MEK functional active signature genes and 13 CRes genes (8) . For each gene, three distinct probe pairs were generated. One pair was designed to be as close as possible to the Affymetrix gene probe ID transcript sequences used to generate the pre-clinical cell line Affymetrix data, while maintaining hybridization functionality (Affymetrix NS Probe). One pair had an identical design across two distinct codesets and was used to test batch reproducibility (Batch Comparison Probe). The remaining pair was designed against any other suitable transcript region of the gene (New Probe). NanoString was only able to generate two specific probes for certain genes (Supplementary Table S1 shows probe designs). The codeset also comprised one probe pair per gene for the 147 genes (RAS signature; 105 up and 42 down) (9) reference genes were included (ABCF1, ACTB, ALAS1, B2M, CLTC, G6PD,   GAPDH, GUSB, HPRT1, LDHA, PGK1, POLR1B, POLR2A, RPL19, RPLP0, TBP, and TUBB). For the complete list of genes, see Supplementary Table S2 .
NanoString data analysis and signature scoring
Transcript counts were normalized between samples in a particular study using an in-house built tool (NAPPA, publicly available on the Comprehensive R Archive Network, CRAN, Harbron & Wappett (2014) R package: NAPPA http://CRAN.Rproject.org/package=NAPPA). Only sample data with a mean Housekeeper (HK) count greater than 50 were processed. Data were Log2 transformed after being normalized in two steps: raw NanoString counts were background adjusted with a Truncated Poisson correction using negative control probes (External RNA Controls Consortium approved designed not to bind with any known organism) followed by a technical normalization using integral positive control spike-ins. Data were then corrected for input amount variation through a Sigmoid shrunken slope normalization step using the GEO mean expression of housekeeping genes. Transcripts were designated as "not detected" if the raw count was less than the average of the negative control raw counts plus two standard deviations.
Signature scores were generated from the normalized Log2 transformed data as previously described (8, 9) .
Research. Housekeeper gene expression was analyzed in the study of 50 FFPET NSCLC samples using three alternative sets of housekeepers: all of the proposed genes, a set that removed the bottom five (ranked according to Spearman Rank Correlation R value of each HK with the mean HK value), and a set that removed the bottom 10 genes.
Analysis of 50 NSCLC FFPET samples into hypothetical treatment groups was performed by setting thresholds of either the 75th percentile of signature scores or by calculating the Youden (27) optimal cut-off for differentiating KRAS mutants within the dataset.
Cell line samples
Cell lines were obtained directly from the ATCC (http://www.atcc.org/) cell bank and passaged in our laboratory for fewer than 6 months after receipt or resuscitation.
Human cell lines were authenticated by ATCC using morphology, karyotyping, and PCR based approaches to confirm identity and to rule out both intra-and interspecies contamination. A549 cells (KRAS-mutant) were cultured in DMEM Since published prioritization was based on pan-cancer data, we aimed to refine the "MEK activation signature" and focus on genes that demonstrated a more robust performance specifically within NSCLC. Using the same tests described and referenced above, we assessed which of the 18 genes maintained these criteria specifically and reproducibly within multiple NSCLC sample sets from cancer cell lines, xenograft/explant models, and patients (8, (17) (18) (19) (20) 29 ). Six genes consistently tested positive in all lung cancer datasets: PHLDA1, SPRY2, DUSP6, DUSP4, ETV4, and ETV5.
Using this lung-optimized MEK signature, we aimed to develop a clinical assay with NanoString nCounter gene expression technology to measure transcription profiles in NSCLC FFPET.
Transfer of the lung-optimized MEK signature to the NanoString platform
The lung-optimized MEK signature comprises only six genes and hence could be more susceptible to changes in methodology than a signature comprising an order of magnitude more genes. Two or three NanoString probes per gene were evaluated and expression compared with Affymetrix data from lung cancer cell lines with a range of signature scores. Fig. 1 shows the correlation plots of historical Affymetrix data and NanoString data for each MEK signature gene using the 'Affymetrix NS Probe'. Pearson correlation coefficients were r of 0.75 or greater for 'Affymetrix NS Probe' data when compared to Affymetrix data, except for ETV5 (r of 0.67).
NanoString data for 'Batch Comparison' and 'New' probes also correlated well with Affymetrix data, except for ETV5 (both probes) and DUSP6 ('Batch Comparison' Probe only). DUSP6, ETV5, and SPRY2 'Affymetrix NS Probe' data correlated better to Affymetrix data than their other gene probes, whereas DUSP4, ETV4, and PHLDA1 gave equivalent or better correlations with Affymetrix data with the "Batch Comparison" and "New" probes (Supplementary Table S3 ).
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Pathway intervention modulates signatures
To investigate the ability of NanoString to detect changes in signature score, we studied the effects of selumetinib, a MEKi, and KRAS siRNA on three lung cancer cell lines (Calu6, NCI-H1437, and NCI-H460). Supplementary Fig. S1 shows the effect of selumetinib (0. 
Development of NanoString gene expression assay for NSCLC FFPET gene signature analysis
The proposed clinical NanoString gene expression assay described above not only represents a change in the technology platform but also sample type requirements (i.e., from cell or frozen tumor lysate to FFPET). We tested the performance of the MEK, CRes, and RAS signatures in a sample type and quantity consistent with that available in standard clinical practice. To study the signature's ability to identify 
mutant) using one 5 µm section per tumor. Operators were blinded to KRAS status.
Of the 50 FFPET samples, four had lower than the optimum 100 ng of RNA following extraction, and 59-97 ng RNA were used in the NanoString assay.
Prior to testing the association between signature output and KRAS status, the optimal choice of reference or HK genes and most suitable endogenous gene probes was determined. Suitability of HK genes and stability of expression results were 
Association with KRAS status in blinded study of 50 NSCLC FFPET tumors
Previous work on the 50 NSCLC samples (choice of HK genes, probes for the MEK signature score, and algorithm for MEK signature calculation) was performed blind to KRAS status. The results ( Fig. 2A) with signature scores lower than the mean of all 50 scores, suggesting they did not have such a high MEK pathway activation. As expected, the difference between KRAS-mutant and KRAS mutation not detected signature scores was greater for the RAS signature. Furthermore, when MEK and CRes signature scores were added, the score closely resembled that of the RAS signature ( Supplementary Fig. S4 ), agreeing with the hypothesis that these signatures measure independent components of KRAS signaling that is captured in totality when combined.
MEK signature score defines a different patient population compared with RAS signature and KRAS mutation
To determine if the signatures and KRAS mutation status identified different patient populations, we compared signature scores obtained for the NSCLC samples with and without KRAS mutations (Fig. 2B) . Patient populations were defined by imposing thresholds of either the 75th percentile of signature scores or by calculating the Youden's J statistic (27) . Youden cut-off seeks the optimal cut-off for differentiating KRAS-mutants within the dataset, by calculating the cut-off value that differs maximally from the pure chance line of a ROC curve. Despite both signatures having statistically significant associations with KRAS status, there was very little correlation between them (Pearson correlation coefficient r = 0.016). This suggests that, in the clinical setting, different patient populations would be eligible for MEKi treatment depending on the biomarker used for patient selection (Fig. 2B) . In order to test the association with mutation status, we deliberately chose to analyze a cohort enriched for KRAS mutations. Thus we modeled the impact of signature testing versus mutation testing using the actual prevalence of KRAS mutations in NSCLC of We examined the ability to reduce RNA input concentrations using samples at a range of signature scores. Samples were serially diluted 2-fold from 100 ng RNA to 3.13 ng and scores calculated. Signatures were relatively consistent down to 25 ng for all samples (Fig. 3) , suggesting that clinical samples yielding sub-optimal RNA quantities generate reliable signature scores. In addition, the LOD was studied with a predetermined 'low' score sample (data not shown). MEK signature genes were expressed above the LOD in all but the lowest RNA concentration, where two of the six genes were not detected. Of the 147 RAS signature genes, the number detected below the LOD increased with decreasing RNA input; concentrations of RNA 100, 50, 25, 12.5, 6.25, and 3.13 ng gave 0 (0%), 5 (3.4%), 13 (8.9%), 21 (14.4%), 31 (21.2%), and 40 (27.4%) undetected RAS signature genes, respectively. Overall, the results demonstrate that the assay is robust and that scores are conserved when sub-optimal amounts of RNA are assayed.
We also examined the reproducibility of expression measured by the NanoString assay upon repeat testing with a different manufacturing batch of probes. Fig. S5 ).
Spatial and temporal conservation of signature scores in NSCLC tumors
For a gene signature to have clinical utility as a biomarker assay, intra-patient variability needs to be lower than inter-patient variability. We studied four NSCLC FFPET samples and compared the MEK and RAS gene expression profiles across different sections throughout the same patient tumor. Samples were selected on their previous MEK or RAS signature score (i.e., low, medium, or high scores).
Tumor blocks were sectioned from the top, 50 µM from the top (middle), and from the bottom. Fig. 4A shows that MEK signature scores were conserved throughout the tumor. Additionally, technical replicates across all sections of the same tumor were comparable. Similar results were shown for the RAS signature scores (Fig. 4B ).
An important, yet frequently untested, assumption is that biomarker data derived from diagnostic tumor samples are sufficiently relevant to direct the treatment of subsequent disease. The assumption can be tested by examining the longitudinal concordance of assay results and tumor biology. We tested the hypothesis that gene signature scores would be conserved between primary and metastatic disease and that this would be maintained regardless of KRAS mutation status. MEK signature scores were conserved across primary and metastatic tumor from 20 patients (Fig. 5A) . Statistical analysis confirmed the variability in the signature profiles between patients was nearly 3-fold greater than the variability between primary and 
metastatic tumor of the same patient. Similar results were achieved for RAS signature, but with a 3.5-fold difference in the variability (Fig. 5B) .
Discussion
NanoString nCounter technology provides a means to test the prognostic and predictive capabilities of gene expression signatures in NSCLC FFPET. We developed a clinically relevant, robust NanoString assay using a lung-optimized gene signature to measure MEK pathway output in NSCLC.
Our 6-gene lung-optimized MEK signature was developed using the process and criteria described by Dry et al (8) . We transferred the lung-optimized MEK signature to the NanoString platform and demonstrated that signature gene expression was robust across both Affymetrix and NanoString platforms. Moreover, the majority of the NanoString probes were successful in measuring their target gene in cell lines.
We investigated the ability of NanoString to detect changes in signature score by studying the effects of selumetinib and KRAS siRNA on three lung cancer cell lines.
The differential effects we observed with KRAS siRNA on the cell lines support the six-gene signature's postulated ability to measure MEK pathway output when assayed on the NanoString and that the MEK signature is more specific to MEK signaling than the RAS signature.
Subsequently, we tested the NanoString gene expression assay in FFPET samples that were consistent with those available in standard clinical practice. We determined which HK genes to use for data normalization, selected the most suitable MEK and CRes probes, and showed detectable MEK signature genes expression in all samples and measurable RAS signature expression for the majority of genes in most samples. The optimized probe selection and HK genes were incorporated into the analysis and used for the calculation of signature scores. 
Calculating the MEK and CRes signature scores by averaging Log2 normalized expression data across genes was deemed acceptable, as the expression range for all of the MEK and CRes genes spanned approximately four logs. If, however, the dynamic range of expression varied greatly for some but not all genes, this could skew the score and, with our method of calculation, not accurately represent the pathway activation status. This was not a concern with RAS signature analysis because scores were calculated by taking away the mean of 'down-regulated genes' from mean of 'up-regulated' genes (regulated up or down in response to RAS pathway output increases) (9) .
NSCLC tumor samples are frequently variable in quality and limited in quantity.
Thus, we investigated the LOD and robustness of the MEK signature to sub-optimal amounts of RNA. Our results showed that gene expression profiles were maintained at reduced RNA starting concentrations and we concluded that 100 ng RNA in a single NSCLC FFPET sample was optimal for NSCLC studies. Tables   Table 1. Signature scores and KRAS mutation status define different patient populations.
Signature scores were dichotomized using the Youden optimal, (i) and (ii), or 75th percentile, (iii) and (iv). Candidate patients are indicated by underlining (KRAS mutated) or bold (signature high or "positive"). Youden cut-off (optimal cut-off that best differentiates between KRAS mutation and mutation not detected status) is shown by dotted lines for both signatures. The mutation status of each sample is denoted by color (red = mutation not detected, black = mutation). Research.
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